In summary, the current study provides evidence showing that the druggable NR HNF4α performs a tumor suppressor function in prostate cancer, by suppressing cellular senescence via its transactivation of CDKN1A (Fig. 8e). The gene discussed is CDKN1A; the disease is prostate carcinoma.